Qiagen (QGEN) said its Digital Insights bioinformatics business will integrate Nvidia's (NVDA) accelerated computing and BioNeMo platform to support researchers using AI for drug discovery.

The integration is intended to help pharmaceutical and biotechnology researchers to better understand disease biology and identify therapeutic targets and biomarkers, the company said Tuesday in a statement.

Qiagen said initial pilot programs will be available to select pharmaceutical and biotechnology partners, with broader availability expected after validation.

Financial details weren't disclosed.